Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 1.00 |
| ▸ | CNR2 | P34972 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.44 |
| ▸ | HTR3A | P46098 | 4/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052482 | 1.00 | CNR1 (1.00) | CNR1CNR2KDM4EACHEHTR4 | |
| SCHEMBL13691214 | 1.00 | CNR1 (1.00) | CNR1CNR2KDM4EACHEHTR4 | |
| SCHEMBL4560432 | 0.91 | CNR1 (0.83) | CNR1CNR2KDM4EACHEHTR4 | |
| SCHEMBL13690513 | 0.90 | CNR1 (0.82) | CNR1CNR2HTR4HTR3AROCK2 | |
| SCHEMBL30641101 | 0.89 | CNR1 (0.80) | CNR1CNR2KDM4EACHEHTR4 | |
| SCHEMBL4051085 | 0.89 | CNR1 (0.80) | CNR1CNR2KDM4EACHEHTR4 | |
| SCHEMBL4053063 | 0.87 | CNR1 (0.77) | CNR1CNR2KDM4EACHEHTR4 | |
| SCHEMBL30473233 | 0.87 | CNR1 (0.77) | CNR1CNR2KDM4EACHEHTR4 | |
| SCHEMBL29993194 | 0.87 | CNR1 (0.77) | CNR1CNR2KDM4EACHEHTR4 | |
| SCHEMBL4049660 | 0.86 | CNR1 (0.76) | CNR1CNR2KDM4EACHEHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3664795-B1 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | CANNIBITE BVBA (BE) | 2024-06-19 | — | — | EP | claimed |
| CN-118063385-A | Hapten for synthesizing cannabinoid ADB-BUTINACA, monoclonal antibody and application thereof | 中国药科大学 | 2024-05-24 | — | — | CN | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-117805259-A | Method for rapidly analyzing 87 synthetic cannabinoids and metabolites thereof in urine after enzymolysis | 司法鉴定科学研究院 | 2024-04-02 | — | — | CN | claimed |
| CN-114942239-B | Composition, kit and method for rapidly detecting synthetic cannabinoid in tobacco tar | 合肥市公安局刑事警察支队 | 2024-02-06 | — | — | CN | claimed |
| CN-113419018-B | Pretreatment method of incense sample and method for detecting various cannabinoids in incense smoke | 福州海关技术中心 | 2022-06-17 | — | — | CN | claimed |
| US-12637447-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective mcl-1 inhibitors and as dual mcl-1/bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4646477-A2 | METHODS AND COMPOSITIONS FOR DISPLAYING PEPTIDE LIBRARIES | Board of Regents, The University of Texas System (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250241933-A1 | METHODS OF TREATING SLEEP APNEA WITH A COMBINATION OF A CANNABINOID AND A CARBONIC ANHYDRASE INHIBITOR | APNIMED, INC. (DELAWARE) | 2025-07-31 | — | — | US | disclosed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| CN-115876920-A | Method for analyzing multiple novel psychoactive substances in food by gas chromatography-mass spectrometry | 三明海关综合技术服务中心 | 2023-03-31 | — | — | CN | disclosed |
| US-11612581-B2 | Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects | CANNIBITE BVBA | 2023-03-28 | — | — | US | disclosed |
| US-20220406587-A1 | MASS SPECTROMETRY METHODS AND RELATED MATERIALS | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| WO-2022221613-A1 | COMBINATION OF A NOREPINEPHRINE REUPTAKE INHIBITOR AND A CANNABINOID FOR USE IN TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022217147-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | ROSENFELD MARK J (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-113419018-B | Pretreatment method of incense sample and method for detecting various cannabinoids in incense smoke | 福州海关技术中心 | 2022-06-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637447-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective mcl-1 inhibitors and as dual mcl-1/bcl-2 inhibitors | MCL1, BCL2L1, BCL2L2 | CNR1 85/4885CNR2 130/4885KDM4E 2932/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR1 221/4885CNR2 204/4885KDM4E 1355/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885KDM4E 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.